CLLS

Cellectis SA is a clinical-stage biotechnology company based in Paris, France, focused on pioneering immuno-oncology therapies through its innovative gene-editing platform. The firm specializes in developing T cell therapies that utilize chimeric antigen receptors (CARs) to precisely target and eradicate cancer cells. With a robust and diverse pipeline of candidates across multiple stages of clinical development, coupled with strategic partnerships, Cellectis is well-positioned to address significant unmet medical needs in oncology and enhance patient outcomes in cancer treatment.